BACH2 and plasma cell myeloma: Finally, CD38, which is an important therapeutic target in multiple myeloma [72] and possibly also in CLL [73], was among the Treg cell signature genes dysregulated in Bach2-deficient T-cells [74], suggesting that decreased expression of BACH2 in CLL could also be related to the decrease in the CD38+ subset of Tfr found in our patients.